Diuretic Versus Placebo in Pulmonary Embolism

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.

Also called NCT02268903

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02268903
Other papers using this trial's data
  • Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial European heart journal. Acute cardiovascular care, 2022-01-12 DOI, PubMed 34632490

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02268903. Randomized; quadruple masking; primary purpose treatment. Start 2015-04-13 (actual); primary completion 2018-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Diuretic Versus Placebo in Pulmonary Embolism
Acronym
DiPER
Condition
Pulmonary Embolism With Right Ventricle Enlargement
Intervention (Drug)
Diuretics : Furosemide
Intervention (Drug)
Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct02268903
Content hash
ab83892986a15005fa6bf7d52975bddd15f4d7b465ab2212020780ec587b0b96